L26/O-320 A multiplexed single-sperm functional assay improves diagnostic accuracy and enables targeted compound screening in male infertility
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Wu und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Can a multiplexed single-sperm functional assay integrating pHi, β-gal activity, and mtG4 structures improve diagnostic accuracy and facilitate targeted drug screening in male infertility? Summary answer The multiplexed assay significantly enhanced diagnostic model performance and identified hydroxycamptothecin and luteolin as compounds capable of rescuing sperm functional deficits. What is known already Conventional semen analysis, based on parameters such as concentration, motility, and morphology, remains the cornerstone of male infertility diagnosis but provides limited insight into sperm functional competence. Growing evidence indicates that these routine parameters correlate poorly with natural fertility and assisted reproductive outcomes. Sperm mitochondrial dysfunction is increasingly recognized as a key contributor to infertility, manifesting through alterations in intracellular pH (pHi), accumulation of senescence-associated β-galactosidase (β-gal), and stabilization of mitochondrial DNA G-quadruplex (mtG4) structures. However, these functional biomarkers are not assessed in clinical practice, and no integrated platform exists for their simultaneous evaluation in individual spermatozoa. Study design, size, duration Diagnostic test study with two independent cohorts. Training cohort: n = 56 from Hospital 1; validation cohort: n = 74 from Hospital 2. Study conducted between 2022–2026. Participants/materials, setting, methods The study analyzed semen samples from two independent clinical cohorts comprising 130 participants. Washed spermatozoa were simultaneously stained with three fluorescent probes targeting pHi, β-gal activity and mtG4 structures. The derived biomarker values, along with conventional clinical parameters, were used to construct and validate multivariate logistic regression models. For drug discovery, sperm samples from infertile patients were incubated with a library of natural compounds in a 96-well plate format, and biomarker responses were quantified fluorometrically. Main results and the role of chance The multiplexed assay successfully quantified three functional sperm biomarkers with high specificity. In clinical validation, integrating these biomarkers, intracellular pH, β-galactosidase activity, and mitochondrial G-quadruplex levels, into a diagnostic model significantly outperformed conventional semen analysis. In the training cohort (n = 56), the area under the receiver operating characteristic curve (AUC) for predicting infertility increased from 0.87 (95% CI: 0.79–0.96) using standard parameters alone to 0.93 (95% CI: 0.87–0.99) with the integrated model (p < 0.001). This superior performance was robustly validated in an independent external cohort (n = 74), where the AUC improved from 0.82 (95% CI: 0.68–0.96) to 0.89 (95% CI: 0.79–0.98) (p < 0.01). Decision curve and calibration curve analyses further confirmed the superior clinical utility and fit of the integrated model. Subsequent high-throughput screening of 45 natural compounds using this platform identified hydroxycamptothecin as a hit that significantly increased sperm pHi, and luteolin as a hit that effectively reduced both mtG4 and β-gal levels. Functional validation in sperm from asthenozoospermic patients showed both compounds improved mitochondrial membrane potential. In mouse models of sperm dysfunction, luteolin treatment rescued early embryonic metabolic profiles, and both compounds improved fertilization and blastocyst formation rates using cryopreserved sperm. Limitations, reasons for caution Sample size remains moderate; all participants were from Chinese populations. External validation in broader ethnic groups is needed. Drug screening was performed ex vivo; in vivo efficacy requires further study. Wider implications of the findings This platform provides a functional, biomarker-driven approach to male infertility diagnosis and personalized treatment screening. It bridges diagnostic assessment with targeted therapeutic discovery, offering a translational pathway beyond descriptive semen analysis. Trial registration number No
Zitieren
APA
Wu, S., & Xu, W. (2026). L26/O-320 A multiplexed single-sperm functional assay improves diagnostic accuracy and enables targeted compound screening in male infertility. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.318
Vancouver
Wu S, Xu W. L26/O-320 A multiplexed single-sperm functional assay improves diagnostic accuracy and enables targeted compound screening in male infertility. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.318
BibTeX
@article{Wu2026,
author = {Wu, S. and Xu, W.},
title = {L26/O-320 A multiplexed single-sperm functional assay improves diagnostic accuracy and enables targeted compound screening in male infertility},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.318}
}
EUVIMED